218 related articles for article (PubMed ID: 30313101)
1. Safety and efficacy of combining capecitabine and temozolomide (CAPTEM) to treat advanced neuroendocrine neoplasms: A meta-analysis.
Lu Y; Zhao Z; Wang J; Lv W; Lu L; Fu W; Li W
Medicine (Baltimore); 2018 Oct; 97(41):e12784. PubMed ID: 30313101
[TBL] [Abstract][Full Text] [Related]
2. Temozolomide Alone or Combined with Capecitabine for the Treatment of Metastatic Neuroendocrine Neoplasia: A "Real-World" Data Analysis.
Bongiovanni A; Liverani C; Foca F; Fausti V; Di Menna G; Mercatali L; De Vita A; Riva N; Calpona S; Miserocchi G; Spadazzi C; Cocchi C; Ibrahim T
Neuroendocrinology; 2021; 111(9):895-906. PubMed ID: 33221806
[TBL] [Abstract][Full Text] [Related]
3. A retrospective study of capecitabine/temozolomide (CAPTEM) regimen in the treatment of metastatic pancreatic neuroendocrine tumors (pNETs) after failing previous therapy.
Saif MW; Kaley K; Brennan M; Garcon MC; Rodriguez G; Rodriguez T
JOP; 2013 Sep; 14(5):498-501. PubMed ID: 24018594
[TBL] [Abstract][Full Text] [Related]
4. Capecitabine-Temozolomide in Advanced Grade 2 and Grade 3 Neuroendocrine Neoplasms: Benefits of Chemotherapy in Neuroendocrine Neoplasms with Significant 18FDG Uptake.
Ostwal V; Basu S; Bhargava P; Shah M; Parghane RV; Srinivas S; Chaudhari V; Bhandare MS; Shrikhande SV; Ramaswamy A
Neuroendocrinology; 2021; 111(10):998-1004. PubMed ID: 33017827
[TBL] [Abstract][Full Text] [Related]
5. Activity and Safety of Standard and Prolonged Capecitabine/Temozolomide Administration in Patients with Advanced Neuroendocrine Neoplasms.
Chatzellis E; Angelousi A; Daskalakis K; Tsoli M; Alexandraki KI; Wachuła E; Meirovitz A; Maimon O; Grozinsky-Glasberg S; Gross D; Kos-Kudła B; Koumarianou A; Kaltsas G
Neuroendocrinology; 2019; 109(4):333-345. PubMed ID: 31167197
[TBL] [Abstract][Full Text] [Related]
6. The Role of Capecitabine/Temozolomide in Metastatic Neuroendocrine Tumors.
Ramirez RA; Beyer DT; Chauhan A; Boudreaux JP; Wang YZ; Woltering EA
Oncologist; 2016 Jun; 21(6):671-5. PubMed ID: 27226359
[TBL] [Abstract][Full Text] [Related]
7. Capecitabine and Temozolomide in Advanced Lung Neuroendocrine Neoplasms.
Al-Toubah T; Morse B; Strosberg J
Oncologist; 2020 Jan; 25(1):e48-e52. PubMed ID: 31455747
[TBL] [Abstract][Full Text] [Related]
8. Capecitabine and Temozolomide as a Promising Therapy for Advanced Thymic Atypical Carcinoid.
Wang X; Li Y; Duan J; Chen Y; Yuan B; Qi Z; Tan H
Oncologist; 2019 Jun; 24(6):798-802. PubMed ID: 30413666
[TBL] [Abstract][Full Text] [Related]
9. Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience.
Fine RL; Gulati AP; Krantz BA; Moss RA; Schreibman S; Tsushima DA; Mowatt KB; Dinnen RD; Mao Y; Stevens PD; Schrope B; Allendorf J; Lee JA; Sherman WH; Chabot JA
Cancer Chemother Pharmacol; 2013 Mar; 71(3):663-70. PubMed ID: 23370660
[TBL] [Abstract][Full Text] [Related]
10. Temozolomide in Grade 3 Gastroenteropancreatic Neuroendocrine Neoplasms: A Multicenter Retrospective Review.
Chan DL; Bergsland EK; Chan JA; Gadgil R; Halfdanarson TR; Hornbacker K; Kelly V; Kunz PL; McGarrah PW; Raj NP; Reidy DL; Thawer A; Whitman J; Wu L; Becker C; Singh S
Oncologist; 2021 Nov; 26(11):950-955. PubMed ID: 34342086
[TBL] [Abstract][Full Text] [Related]
11. Temozolomide-based combination for advanced neuroendocrine neoplasms: a systematic review of the literature.
Abdel-Rahman O; Fouad M
Future Oncol; 2015; 11(8):1275-90. PubMed ID: 25832882
[TBL] [Abstract][Full Text] [Related]
12. Capecitabine and Temozolomide (CAPTEM) in Advanced Neuroendocrine Neoplasms (NENs): A Systematic Review and Pooled Analysis.
Arrivi G; Verrico M; Roberto M; Barchiesi G; Faggiano A; Marchetti P; Mazzuca F; Tomao S
Cancer Manag Res; 2022; 14():3507-3523. PubMed ID: 36575665
[TBL] [Abstract][Full Text] [Related]
13. The optimal duration of capecitabine plus temozolomide in patients with well-differentiated pancreatic NETs with or without maintenance therapy.
Gao H; Dong J; Zhang W; Xu H; Ye L; Li H; Wang W; Liu L; Yu X
J Neuroendocrinol; 2022 Jun; 34(6):e13112. PubMed ID: 35380016
[TBL] [Abstract][Full Text] [Related]
14. Capecitabine and Temozolomide in Patients with Advanced Pulmonary Carcinoid Tumours.
Papaxoinis G; Kordatou Z; McCallum L; Nasralla M; Lamarca A; Backen A; Nonaka D; Mansoor W
Neuroendocrinology; 2020; 110(5):413-421. PubMed ID: 31437838
[TBL] [Abstract][Full Text] [Related]
15. Capecitabine plus temozolomide in well- or moderately-differentiated primary atypical neuroendocrine tumours - single-centre experience of two cases.
La Salvia A; Brizzi MP; Muratori L; Trevisi E; Di Maio M; Scagliotti GV
Endokrynol Pol; 2019; 70(4):380-383. PubMed ID: 30359462
[TBL] [Abstract][Full Text] [Related]
16. Sequential Capecitabine/Temozolomide and Sunitinib Treatment in Patients With Metastatic Well-Differentiated Grade 1/Grade 2 Pancreatic Neuroendocrine Tumors.
Gao H; Dong J; Zhang W; Xu H; Ye L; Li H; Ni Q; Wang W; Liu L
Endocr Pract; 2022 Mar; 28(3):292-297. PubMed ID: 34454077
[TBL] [Abstract][Full Text] [Related]
17. Capecitabine plus temozolomide in patients with grade 3 unresectable or metastatic gastroenteropancreatic neuroendocrine neoplasms with Ki-67 index <55%: single-arm phase II study.
Jeong H; Shin J; Jeong JH; Kim KP; Hong SM; Kim YI; Ryu JS; Ryoo BY; Yoo C
ESMO Open; 2021 Jun; 6(3):100119. PubMed ID: 33901869
[TBL] [Abstract][Full Text] [Related]
18. Phase I-II study of radiopeptide 177Lu-octreotate in combination with capecitabine and temozolomide in advanced low-grade neuroendocrine tumors.
Claringbold PG; Price RA; Turner JH
Cancer Biother Radiopharm; 2012 Nov; 27(9):561-9. PubMed ID: 23078020
[TBL] [Abstract][Full Text] [Related]
19. A Ki-67 Index to Predict Treatment Response to the Capecitabine/Temozolomide Regimen in Neuroendocrine Neoplasms: A Retrospective Multicenter Study.
Wang W; Zhang Y; Peng Y; Jin KZ; Li YL; Liang Y; Tan HY; Yu XJ; Zhou ZW; Chen J
Neuroendocrinology; 2021; 111(8):752-763. PubMed ID: 32668427
[TBL] [Abstract][Full Text] [Related]
20. Analysis of potential response predictors to capecitabine/temozolomide in metastatic pancreatic neuroendocrine tumors.
Cives M; Ghayouri M; Morse B; Brelsford M; Black M; Rizzo A; Meeker A; Strosberg J
Endocr Relat Cancer; 2016 Sep; 23(9):759-67. PubMed ID: 27552969
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
